Meridian Wealth Management LLC Makes New $201,000 Investment in TransMedics Group, Inc. $TMDX

Meridian Wealth Management LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,502 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds also recently made changes to their positions in TMDX. Amalgamated Bank grew its stake in TransMedics Group by 0.8% in the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after purchasing an additional 80 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after buying an additional 135 shares in the last quarter. CWM LLC grew its position in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after buying an additional 155 shares during the period. Maryland State Retirement & Pension System grew its position in shares of TransMedics Group by 1.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 9,943 shares of the company’s stock worth $1,332,000 after buying an additional 185 shares during the period. Finally, Opal Wealth Advisors LLC bought a new position in shares of TransMedics Group in the 2nd quarter worth about $26,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $117.07 on Wednesday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $145.50. The firm has a market cap of $4.00 billion, a P/E ratio of 47.40 and a beta of 2.05. The company has a 50 day moving average of $119.16 and a 200 day moving average of $120.33. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company’s revenue was up 32.2% compared to the same quarter last year. During the same period last year, the business posted $0.12 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on TMDX. Evercore ISI began coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective on the stock. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Canaccord Genuity Group boosted their price target on TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Finally, Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.